GlassScriptPhysician profile
Adrian Dobrescu
NPI 1336316959
$6,570.57
in general payments reported to CMS, 2019-2025
35 companies · $2,071 in 2025
The $2,071 reported for 2025 was more than what 77% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.23 · 2020: $120 · 2021: $614 · 2022: $732 · 2023: $1,260 · 2024: $1,719 · 2025: $2,071.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,967 · Education: $82.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,967.21 |
| Education | $82.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,316.64 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $622.97 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $586.79 | 2023-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $361.15 | 2021-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $330.13 | 2021-2025 | Adbry, Anzupgo |
| Abbvie INC. | $283.37 | 2020-2025 | Rinvoq |
| Galderma Laboratories, L.P. | $254.76 | 2019-2025 | Aklief, Oracea, Epsolay |
| Pfizer INC. | $244.96 | 2020-2025 | |
| Kerecis Limited | $241.62 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Ucb, INC. | $227.41 | 2022-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $224.57 | 2021-2025 | |
| Dermavant Sciences, INC. | $188.92 | 2023 | Vtama |
| Allergan, INC. | $185.35 | 2020-2022 | |
| Incyte Corporation | $160.11 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $150.62 | 2019-2025 | Winlevi, Absorica Ld |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $148.32 | 2021-2025 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $135.61 | 2019-2024 | Arazlo, Jublia, Cabtreo |
| Motiva USA, LLC | $127.12 | 2025 | |
| Verrica Pharmaceuticals INC. | $122.93 | 2023-2025 | Ycanth |
| Medimetriks Pharmaceuticals, INC. | $88.63 | 2024-2025 | Clindacin Etz, Neo-Synalar |
| Organogenesis INC. | $72.00 | 2024-2025 | Novachor |
| Revance Therapeutics, INC. | $66.39 | 2024 | Daxxify |
| Mayne Pharma Commercial LLC | $60.14 | 2020-2025 | |
| Journey Medical Corporation | $55.97 | 2022-2025 | |
| Almirall LLC | $52.31 | 2021-2025 | Klisyri |
| Biofrontera INC. | $47.08 | 2022-2025 | Rhodoled Xl, Ameluz, Xepi |
| Lilly USA, LLC | $46.26 | 2023-2024 | Taltz, Ebglyss |
| Organon LLC | $44.80 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $24.92 | 2025 | Zoryve |
| Lnhc, INC | $24.22 | 2025 | Zelsuvmi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.56 | 2024 | Spevigo |
| Smith+Nephew, INC. | $17.63 | 2024 | Collagenase Santyl |
| Mimedx Group, INC. | $14.44 | 2025 | |
| Aclaris Therapeutics, INC. | $14.39 | 2019 | |
| Reprise Biomedical, INC. | $4.48 | 2025 | Miro3d |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Dobrescu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.